Jean Bousquet1,2,3,4, Detlef Schröder-Bernhardi5, Claus Bachert6,7,8,9, G Walter Canonica10, Victoria Cardona11, Elisio M Costa12, Wienczyslawa Czarlewski13, Philippe Devillier14, Joao A Fonseca15,16, Ludger Klimek17,18,19, Piotr Kuna20, Olga Lourenco21, Joaquim Mullol22,23, Oliver Pfaar24, Nhân Pham-Thi25, Boleslaw Samolinski26, Julia Saueressig5, Glenis K Scadding27, Ann-Kathrin Stroh5, Sophie Scheire28, Eric Van Ganse29,30, Torsten Zuberbier1,2. 1. Charité Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany. 2. Department of Dermatology and Allergy, Comprehensive Allergy Center, Berlin Institute of Health, Berlin, Germany. 3. University Hospital Montpellier, Montpellier, France. 4. MACVIA-France, Montpellier, France. 5. IQVIA Consumer Health, Frankfurt, Germany. 6. Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium. 7. International Airway Research Center, First Affiliated Hospital Guangzou, Sun Yat-sen University, Guangzou, China. 8. Division of ENT Diseases, CLINTEC, Karolinska Institutet, Stockholm, Sweden. 9. Department of ENT Diseases, Karolinska University Hospital, Stockholm, Sweden. 10. Personalized Medicine Asthma, & Allergy Clinic-Humanitas University & Research Hospital, IRCCS-Milano, Milano, Italy. 11. Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL Research Network, Barcelona, Spain. 12. UCIBIO, REQUINTE, Faculty of Pharmacy and Competence Center on Active and Healthy Ageing of University of Porto (Porto4Ageing), Porto, Portugal. 13. Medical Consulting Czarlewski, Levallois, France. 14. Unité de Recherche en Pharmacologie Respiratoire, Pôle des Maladies des Voies Respiratoires, Hôpital Foch, Université Paris-Saclay, Suresnes, France. 15. CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Lda Porto, Portugal. 16. Medida, Lda Porto, Portugal. 17. Center Department of Otolaryngology, Head and Neck Surgery, Universitätsmedizin Mainz, Mainz, Germany. 18. Center for Rhinology and Allergology, Wiesbaden, Germany. 19. Department of Otolaryngology, Head and Neck Surgery, Universitätsmedizin Mainz, Mainz, Germany. 20. Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland. 21. Faculty of Health Sciences and CICS - UBI, Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal. 22. Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, Barcelona, Spain. 23. Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain. 24. Section of Rhinology and Allergy, Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany. 25. Ecole Polytechnique Palaiseau, IRBA (Institut de Recherche bio-Médicale des Armées), Bretigny, France. 26. Department of Prevention of Environmental Hazards, Allergology and Immunology, Medical University of Warsaw, Warsaw, Poland. 27. The Royal National ENT Hospital, University College London, London, UK. 28. Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. 29. PELyon, Lyon, France. 30. HESPER 7425, Health Services and Performance Research, Université Claude Bernard Lyon, Lyon, France.
Abstract
BACKGROUND: The practice of allergology varies widely between countries, and the costs and sales for the treatment of rhinitis differ depending on practices and health systems. To understand these differences and their implications, the rhinitis market was studied in some of the EU countries. METHODS: We conducted a pharmaco-epidemiological database analysis to assess the medications that were being prescribed for allergic rhinitis in the years 2016, 2017 and 2018. We used the IQVIA platforms for prescribed medicines (MIDAS®- Meaningful Integration of Data, Analytics and Services) and for OTC medicines (OTC International Market Tracking-OTCims). We selected the five most important markets in the EU (France, Germany, Italy, Poland and Spain). RESULTS: Intranasal decongestants were excluded from the analyses because they are rarely prescribed for allergic rhinitis. For both Standard Units (SU) and costs, France is leading the other countries. In terms of SU, the four other countries are similar. For costs, Poland is lower than the three others. However, medication use differs largely. For 2018, in SU, intranasal corticosteroid is the first treatment in Poland (70.0%), France (51.3%), Spain (51.1%) and Germany (50.3%), whereas the Italian market is dominated by systemic antihistamines (41.4%) followed by intranasal corticosteroids (30.1%). Results of other years were similar. DISCUSSION: There are major differences between countries in terms of rhinoconjunctivitis medication usage.
BACKGROUND: The practice of allergology varies widely between countries, and the costs and sales for the treatment of rhinitis differ depending on practices and health systems. To understand these differences and their implications, the rhinitis market was studied in some of the EU countries. METHODS: We conducted a pharmaco-epidemiological database analysis to assess the medications that were being prescribed for allergic rhinitis in the years 2016, 2017 and 2018. We used the IQVIA platforms for prescribed medicines (MIDAS®- Meaningful Integration of Data, Analytics and Services) and for OTC medicines (OTC International Market Tracking-OTCims). We selected the five most important markets in the EU (France, Germany, Italy, Poland and Spain). RESULTS: Intranasal decongestants were excluded from the analyses because they are rarely prescribed for allergic rhinitis. For both Standard Units (SU) and costs, France is leading the other countries. In terms of SU, the four other countries are similar. For costs, Poland is lower than the three others. However, medication use differs largely. For 2018, in SU, intranasal corticosteroid is the first treatment in Poland (70.0%), France (51.3%), Spain (51.1%) and Germany (50.3%), whereas the Italian market is dominated by systemic antihistamines (41.4%) followed by intranasal corticosteroids (30.1%). Results of other years were similar. DISCUSSION: There are major differences between countries in terms of rhinoconjunctivitis medication usage.
Authors: Rafael José Vieira; Bernardo Sousa-Pinto; Josep M Anto; Aziz Sheikh; Ludger Klimek; Torsten Zuberbier; João Almeida Fonseca; Jean Bousquet Journal: World Allergy Organ J Date: 2022-06-24 Impact factor: 5.516